Zentalis Pharmaceuticals, Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Zentalis Pharmaceuticals completed a registered direct offering of 23,000,000 common shares at $3.50 per share (public price), generating gross proceeds of approximately $80.35 million before underwriting fees (~$5.6M at 7% discount). The underwriters—TD Securities, Guggenheim Securities, and Oppenheimer & Co.—also received a 30-day option to purchase up to 3,450,000 additional shares at the same price. Lock-up agreements restrict insiders from selling for 60 days post-prospectus. The company's market value is approximately $66.9M.
Why this rating
At ~$66.9M market cap, $80M gross proceeds equals 120% of company size—transformational capital raise. Dilutes existing shareholders ~34% (23M new shares to estimated 68M pre-offering base). However, raises critical cash for pharma R&D. Significant but not existential.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.